MULTIMODAL ASSAY FOR DETECTING NUCLEIC ACID ABERRATIONS

• US 20190309352A1
• Filed: 11/16/2017
• Published: 10/10/2019
• Est. Priority Date: 11/16/2016
• Status: Abandoned Application

• Current Assignee: Progenity, Inc. (Athyrium Capital Management LP)
• Original Assignee: Progenity, Inc. (Athyrium Capital Management LP)
• Inventors: Buis, Jeffrey, Beaubien, JR., Ronald David, Stoerker, Jay
• Application Number:
  US16/461,211
• Publication Number:
  US 20190309352A1
• Time in Patent Office: Days
• CPC Class Codes: C12Q 1/6806 Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay C12Q1/6804 takes precedence
• CPC Class Codes: C12Q 1/6827 for detection of mutation or polymorphism
• CPC Class Codes: C12Q 1/6858 Allele-specific amplification
• CPC Class Codes: C12Q 2523/125 Bisulfite(s)
• CPC Class Codes: C12Q 2525/151 repeat or repeated sequences, e.g. VNTR, microsatellite, concatemer
• CPC Class Codes: C12Q 2525/155 incorporating/generating a new priming site
• CPC Class Codes: C12Q 2525/161 incorporating target specific and non-target specific sites
• CPC Class Codes: C12Q 2525/307 Circular oligonucleotides
• CPC Class Codes: C12Q 2535/122 Massive parallel sequencing
• CPC Class Codes: C12Q 2549/119 using nested primers
• CPC Class Codes: C12Q 2563/179 the label being a nucleic acid
• CPC Class Codes: C12Q 2565/514 characterised by the use of the arrayed oligonucleotides as identifier tags, e.g. universal addressable array, anti-tag or tag complement array

Abstract

The invention provides methods for determining whether a subject is predisposed to the disease or condition, or for diagnosing a disease or condition, or for detecting the state of a disease or condition, by detecting nucleic acid fragment size patterns, copy number variations, mutational landscape, genomic instability, methylation status, and combinations thereof in a subject. The invention further provides methods for selecting nucleic acid molecules for use in the methods of the invention.

Claims

1. A method for determining a nucleotide sequence for one or more target nucleic acids of interest in a subject comprising:

a) obtaining a nucleic acid sample isolated from a subject;

b) adding an anchor sequence to one of the 3′

or 5′

end of a plurality of nucleic acids from the sample in step a) to create an anchor product;

c) hybridizing an anchor primer to the anchor product of step b), wherein the anchor primer is substantially complementary to the anchor sequence from step b), and hybridizing a genome-informed primer, which is substantially complementary to a repeat sequence in the nucleic acid, to produce a plurality of replicons, wherein the anchor sequence and the repeat sequence flank a gap region in the plurality of target nucleic acid sequences of interest;

d) sequencing a plurality of amplicons that are amplified from the replicons in step c) to determine the nucleotide sequence of one or more target nucleic acids.

2. The method of claim 1, wherein the plurality of nucleic acids are single-stranded and the anchor sequence is added via random priming.

3. The method of claim 1, wherein the plurality of nucleic acids are double-stranded and the anchor sequence is added via a ligation reaction.

4. The method of any one of claims 1-3, wherein the anchor primer is a hybridization anchor arm on a capture probe, and the genome-informed primer is a hybridization genome-informed arm on the opposite end of the same capture probe.

5. The method of claim 4, wherein the capture probe is a molecular inversion probe (MIP).

6. The method of any one of claims 1-5, wherein the anchor sequence added to the plurality of nucleic acid sequences in step b) further comprises one or more unique molecular tags.

7. The method of any one of claims 1-6, wherein the anchor sequence added to the plurality of nucleic acid sequences in step b) further comprises one or more linker sequences.

8. The method of any one of claims 1-7, wherein the anchor product of step b), further comprises in sequence the following components:

anchor sequence—

first unique molecular tag—

first polynucleotide linker—

captured target nucleic acid—

second polynucleotide linker.

9. The method of any one of claims 4-8, wherein the capture probe further comprises one or more unique molecular tags.

10. The method of any one of claims 4-9, wherein the capture probe further comprises a backbone sequence.

11. The method of claim 9 or claim 10, wherein the capture probe further comprises in sequence the following components:

anchor arm—

backbone sequence—

genome-informed arm.

12. The method of any one of claims 6-11, further comprising a method for determining a number of capture events of each of a population of amplicons of the plurality of amplicons provided in step d) by counting a number of the unique molecular tags of each capture probe that produced a replicon, wherein the population of amplicons is determined by the sequence of the target sequence of interest.

13. The method of claim 12, wherein the number of capture events is indicative of a capture bias.

14. The method of claim 12, further comprising using the number of unique molecular tags to identify duplicates to improve analysis.

15. The method of any one of claims 1-14, further comprising determining a number of the unique amplicons sequenced at step d);

determining a read density based on or based in part on the number of unique amplicon sequences; and

detecting copy number variation by comparing the read density to a plurality of reference read densities that are computed based on reference nucleic acid samples isolated from reference subjects.

16. The method of claim 15, further comprising determining the number of unique amplicon sequences in defined regions to determine the read density.

17. The method of any one of claims 3-16, wherein the double-stranded plurality of nucleic acids is subjected to end-repair prior to ligation to the anchor sequence.

18. The method of any one of claims 3-16, wherein the double-stranded plurality of nucleic acids is subjected to end-repair and phosphorylation prior to ligation to the anchor sequence.

19. The method of any one of claims 3-16, wherein the double-stranded plurality of nucleic acids is further subjected to end-repair, phosphorylation, and A-tailing prior to ligation to the anchor sequence.

20. The method of any one of claims 17-19, further comprising a bead-based cleanup step after the ligation of the anchor sequence to the plurality of nucleic acids.

21. The method of any one of claims 1-3 and 6-11, wherein the method further comprises, before the sequencing step of d), an extension-ligation step to produce circular replicons.

22. The method of any one of claims 1-21, wherein the method further comprises an exonuclease digestion step that digests non-circular, linear nucleic acids.

23. The method of claim 22, wherein, following the exonuclease digestion, the method further comprises a linearizing step wherein the circular probe is cleaved to become linear.

24. The method of any one of claims 1-23, wherein the method comprises, before the sequencing step of d), a PCR reaction to amplify the replicons thereby producing amplicons for sequencing.

25. The method of claim 24, wherein the PCR reaction is an indexing PCR reaction.

26. The method of claim 25, wherein the indexing PCR reaction introduces into each of the amplicons the following components:

a pair of indexing primers, a unique sample barcode and a pair of sequencing adaptors.

27. The method of claim 26, wherein the barcoded amplicons comprise in sequence the following components:

a first sequencing adaptor—

a first sequencing primer—

an anchor arm hybridizing sequence—

a first unique molecular tag—

a captured target nucleic acid—

a genome-informed arm hybridizing sequence—

the second unique molecular tag—

a unique sample barcode—

a second sequencing primer—

a second sequencing adaptor.

28. The method of any one of claims 1-27, wherein the repeat sequence is selected from the group consisting of Alu repeats, protein binding sites, class switch recombination sites, VDJ recombination sites, D4Z4 repeats, centromeric SAT-α

repeats, NBL2 repeats, and LINE1 sites.

29. The method of any one of claims 1-28, wherein the target sequence of interest is located in an Alu element.

30. The method of any one of claims 1-29, wherein the target sequence of interest is located in the right arm of an Alu element.

31. The method of any one of claims 1-30, wherein the nucleotide sequence of 50,000 or more different target nucleic acids in a subject is determined using a single capture probe.

32. The method of any one of claims 1-31, wherein the amplicon sequence from step d) is used to determine the size of the amplicon.

33. The method of claim 32, wherein the sizes of 1,000 or more different target nucleic acids in the nucleic acid sample are determined using a single capture probe.

34. The method of claim 32 or 33, wherein at least some of the nucleic acids of interest in the subject are cell-free target nucleic acids, the method further comprising:

a) measuring amounts of amplicons from the nucleic acid sample corresponding to each of a plurality of sizes, the amounts comprising amplicons from cell-free target nucleic acids and from background nucleic acids, thereby measuring amounts of nucleic acids at the plurality of sizes;

b) calculating a first value of a first parameter based on the amounts of nucleic acids at the plurality of sizes, the first parameter providing a statistical measure of a size profile of nucleic acids in the sample;

c) comparing the first value to a reference value; and

d) estimating the fractional concentration of the target nucleic acids among background nucleic acid in the sample based on the comparison of step c).

35. The method of claim 34, wherein the cell-free target nucleic acids are of apoptotic origin.

36. The method of claim 34, wherein the cell-free target nucleic acids are of fetal origin, and the background nucleic acids comprise maternal nucleic acids, whereby the concentration of fetal nucleic acids in a sample from a maternal subject is determined.

37. The method of claim 36, wherein the reference value is from one or more pregnant subjects with known concentrations of fetal nucleic acids.

38. The method of claim 34, wherein the cell-free target nucleic acids are from a tumor, and the background nucleic acids comprise non-tumor nucleic acids, whereby the concentration of tumor nucleic acids in a sample is determined.

39. The method of claim 38, the wherein reference value is from one or more cancer-free subjects.

40. The method of claim 34, wherein the cell-free target nucleic acids are from a donor, and the background nucleic acids comprise host nucleic acids, whereby the concentration of transplanted donor nucleic acids in a sample from the host is determined.

41. The method of any one of claims 4-27, further comprising determining the number of unique amplicon sequences to measure copy number variation, wherein the number of unique amplicons is determined by the sequence of the target sequence of interest determined in step d).

42. The method of claim 41, wherein the number of unique amplicon sequences is compared to a known reference.

43. The method of claim 41, further comprising determining a size distribution of each of a population of unique amplicon sequences.

44. The method of any one of claims 4-27, wherein the one or more target nucleic acids from the sample in step a) comprise one or more sequence mutations that are detected by sequencing step d), thereby determining a mutational landscape.

45. The method of claim 44, wherein the one or more sequence mutations is selected from the group consisting of single nucleotide variations, deletions, insertions, translocations, fusions, and repeat expansions.

46. The method of claim 44, wherein 100 or more different sequence mutations are detected by a single capture probe.

47. The method of claim 44, wherein the frequency or type of sequence mutations is compared to a known reference.

48. The method of any one of claims 4-27, wherein a methylation status of one or more target nucleic acids in a subject is determined, the method further comprising:

a) performing bisulfite conversion of the nucleic acid sample;

b) sequencing amplicons from replicons of the bisulfite converted nucleic acid sample; and

c) determining the number of occurrences of cytosine nucleotides at each corresponding known CpG site within the unique amplicons, wherein the methylation status is determined based on the number of occurrences of cytosine nucleotides at each corresponding known CpG site.

49. The method of any one of claims 1-27, wherein nucleosomal occupancy at one or more target nucleic acids in a subject is determined, the method further comprising:

a) hybridizing a genome-informed primer to a protein binding site in one or more target nucleic acids;

b) determining the size of the plurality of amplicons based on the amplicon sequence from step d), thereby determining an amplicon fragmentation pattern, wherein the fragmentation patterns is indicative of nucleosomal occupancy.

50. The method of claim 49, wherein the protein binding site is a transcription factor binding site or a nuclease binding site.

51. The method of claim 49, further comprising comparing the nucleosomal occupancy to a reference nucleosomal occupancy.

52. The method of any one of claims 1-27, wherein a gene fusion event at one or more target nucleic acids in a subject is detected, the method further comprising:

a) hybridizing a genome-informed primer to a gene-specific sequence in one or more target nucleic acids;

b) determining a presence or absence of a gene fusion event based on the amplicon sequence from step d), wherein the presence of two different gene sequences in a single amplicon is indicative of a gene fusion event.

53. The method of any one of claims 49-52, wherein two or more different genome-informed primers are used in a single, multiplexed assay.

54. The method of any one of claims 1-53, wherein the nucleic acid sample is DNA or RNA.

55. The method of claim 54, wherein the nucleic acid sample is genomic DNA.

56. The method of claim 55, wherein the genomic DNA is fragmented.

57. The method of any one of claims 1-55, wherein the sample is a blood sample selected from a whole blood sample, a plasma sample, and a serum sample.

58. The method of claim 57, wherein the blood sample is a plasma sample.

59. The method of any one of claims 1-58, wherein sequencing information is used in the determination of whether the subject has the predisposition to a disease or condition, or used in diagnosing a disease or condition, or used in detecting a state of a disease or condition, or used in differentiating the nucleic acid species originating from the subject and from one or more additional individuals.

60. A method of detecting copy number variation in a subject, comprising:

a) obtaining a nucleic acid sample isolated from a subject;

b) adding an anchor sequence to one of the 3′

or the 5′

end of a plurality of nucleic acid sequences from the sample in step a);

c) capturing a plurality of target sequences of interest in the nucleic acid sample obtained in step a) by using one or more populations of molecular inversion probes (MIPs) to produce a plurality of replicons,

wherein each of the MIPs in the population of MIPs comprises in sequence the following components;

anchor arm—

polynucleotide linker—

genome-informed arm;

wherein the anchor arm in each of the MIPs is substantially complementary to the anchor sequence from step b), and the genome-informed arm in each of the MIPs is substantially complementary to a repeat sequence in the nucleic acid, such that the anchor sequence and the repeat sequence flank a unique gap region in the plurality of target sequences of interest;

d) sequencing a plurality of MIP amplicons that are amplified from the replicons obtained in step c);

e) determining a number of a first population of amplicons of the plurality of amplicons provided in step d) based on the number of unique amplicon sequences;

f) determining a number of each of a second population of amplicons of the plurality of amplicons provided in step d) based on the number of unique amplicon sequences;

g) determining, for each target sequence of interest from which the first population of amplicons was produced, a site capture metric based at least in part on the number of capture events determined in step e);

h) identifying a first subset of the site capture metrics determined in step g) that satisfy at least one criterion;

i) determining, for each target sequence of interest from which the second population of amplicons was produced, a site capture metric based at least in part on the number of capture events determined in step f);

j) identifying a second subset of the site capture metrics determined in step i) that satisfy the at least one criterion;

k) normalizing a first measure determined from the first subset of site capture metrics identified in step h) by a second measure determined from the second subset of site capture metrics identified in step j) to obtain a test ratio;

l) comparing the test ratio to a plurality of reference ratios that are computed based on reference nucleic acid samples isolated from reference subjects without a copy number variation at the target sequences of interest; and

m) determining, based on the comparing in step l), whether a copy number variation is present at the target sequences of interest in a subject.

61. The method of claim 60, wherein the nucleic acid sample is isolated from a maternal blood sample comprising fetal nucleic acid, and the copy number variation is a fetal aneuploidy determined by comparing the test ratio to a plurality of reference ratios that are computed based on reference nucleic acid samples isolated from reference subjects known to exhibit euploidy or aneuploidy.

62. The method of claim 60, wherein the nucleic acid sample is isolated from a maternal blood sample comprising fetal nucleic acid, and a fetal aneuploidy is detected, the method further comprising comparing the distribution of maternal and fetal amplicon sequences from the maternal sample to the normal distribution of amplicon sequences from a euploid chromosome from the same sample, whereby a chromosomal copy number variation is indicative of a fetal aneuploidy.

63. The method of claim 60 or 61, wherein the size of one or more amplicons from the plurality of target sequences is determined based on the amplicon sequence from step d).

64. The method of any one of claims 60-63, wherein the site capture metric comprises a site capture efficiency index (SCE).

65. The method of any one of claims 60-64, wherein the site capture metric comprises a site capture consistency measure (SCC).

66. The method of any one of claims 60-65, wherein each of the MIPs replicons provided in step c) is produced by:

i) the anchor arms and genome-informed arms, respectively, hybridizing to the first and second regions in the nucleic acid sample, respectively, wherein the first and second regions flank a target sequence of interest; and

ii) after the hybridization, using a ligation/extension mixture to extend and ligate the gap region between the two arms to form single-stranded circular nucleic acid molecules.

67. The method of any one of claims 60-66, wherein the method comprises, before the sequencing step of d), performing a PCR reaction to amplify the MIP replicons for sequencing.

68. The method of claim 67, wherein the PCR reaction is an indexing PCR reaction.

69. The method of claim 68, wherein the indexing PCR reaction introduces into each of the MIPs amplicons the following components:

a pair of indexing primers, a unique sample barcode and a pair of sequencing adaptors.

70. The method of claim 69, wherein the barcoded MIPs amplicons comprise in sequence the following components:

a first sequencing adaptor—

a first sequencing primer—

the first unique targeting molecular tag—

the anchor arm—

captured nucleic acid—

the genome-informed arm—

the second unique targeting molecular tag—

a unique sample barcode—

a second sequencing primer—

a second sequencing adaptor.

71. The method of any one of claims 60-70, wherein the first plurality of target sequences of interest is on a single chromosome.

72. The method of any one of claims 60-71, wherein the second plurality of target sequences of interest are on multiple chromosomes.

73. The method of claim 63, wherein at least some of the nucleic acids of interest in the subject are cell-free target nucleic acids, the method further comprising:

a) measuring amounts of amplicons from the nucleic acid sample corresponding to each of a plurality of sizes, the amounts comprising amplicons from cell-free target nucleic acids and from background nucleic acids, thereby measuring amounts of nucleic acids at the plurality of sizes;

b) calculating a first value of a first parameter based on the amounts of nucleic acids at the plurality of sizes, the first parameter providing a statistical measure of a size profile of nucleic acids in the sample;

c) comparing the first value to a reference value; and

d) estimating the fractional concentration of the target nucleic acids among background nucleic acid in the sample based on the comparison of step c).

74. The method of claim 73, wherein the cell-free target nucleic acids are of fetal origin, and the background nucleic acids comprise maternal nucleic acids, whereby the concentration of fetal nucleic acids in a maternal sample is determined.

75. The method of claim 74, wherein the reference value is from one or more pregnant subjects with known concentrations of fetal nucleic acids.

76. The method of claim 73, wherein the cell-free target nucleic acids are from a tumor, and the background nucleic acids comprise non-tumor nucleic acids, whereby the concentration of tumor nucleic acids in a sample is determined.

77. The method of claim 76, wherein the reference value is from one or more cancer-free subjects.

78. The method of claim 73, wherein the cell-free target nucleic acids are from a donor, and the background nucleic acids comprise host nucleic acids, whereby the concentration of transplanted donor nucleic acids in a sample from the host is determined.

79. A method of determining the methylation status of one or more nucleic acid fragments in a subject comprising:

a) obtaining a nucleic acid sample isolated from a subject;

b) performing bisulfite conversion of the nucleic acid sample;

c) adding an anchor sequence to the bisulfite-converted nucleic acid of step b);

d) capturing a plurality of target sequences of interest in the nucleic acid sample obtained in step a) by using one or more populations of molecular inversion probes (MIPs) to produce a plurality of replicons,

wherein each of the MIPs in the population of MIPs comprises in sequence the following components;

anchor arm—

polynucleotide linker—

genome-informed arm;

wherein the anchor arm in each of the MIPs is substantially complementary to the anchor sequence from step c), and the genome-informed arm in each of the MIPs is substantially complementary to a repeat sequence in the nucleic acid, such that the anchor sequence and the repeat sequence flank a unique gap region in the plurality of target sequences of interest;

e) sequencing a plurality of MIP amplicons that are amplified from the replicons obtained in step d); and

f) determining the number of occurrences of cytosine nucleotides at each corresponding known CpG site within the MIP amplicons sequenced at step e), wherein the methylation status is determined based on the number of occurrences of cytosine nucleotides at each corresponding known CpG site.

80. The method of claim 79, wherein the size of one or more amplicons from the plurality of target sequences is determined based on the amplicon sequence from step d).

81. The method of claim 80, wherein at least some of the nucleic acids are cell-free target nucleic acids, the method further comprising:

a) measuring amounts of amplicons from the nucleic acid sample corresponding to each of a plurality of sizes, the amounts comprising amplicons from cell-free target nucleic acids and from background nucleic acids, thereby measuring amounts of nucleic acids at the plurality of sizes;

b) calculating a first value of a first parameter based on the amounts of nucleic acids at the plurality of sizes, the first parameter providing a statistical measure of a size profile of nucleic acids in the sample;

c) comparing the first value to a reference value; and

d) estimating the fractional concentration of the target nucleic acids among background nucleic acid in the sample based on the comparison of step c).

82. The method of claim 79, wherein the methylation status of step e), is compared to a reference value.

83. The method of claim 82, wherein the reference value is a methylation status from a specific tissue type.

84. The method of claim 83, wherein the reference value is a methylation status from a diseased tissue type.

85. A method for characterizing one or nucleic acids of interest from a subject, comprising:

a) obtaining a nucleic acid sample isolated from a subject;

b) adding clip sequences to the 3′ and

5′

ends of each of a plurality of target nucleic acids from the sample in step a) to create a clip product, wherein the two clip sequences flank a gap region in the target nucleic acid sequence of interest;

c) hybridizing a capture probe comprising two clip binding arms to the clip product of step b), wherein the two clip binding arms are on opposite ends of the same capture probe, and wherein each clip binding arm is substantially complementary one of the clip sequences from step b);

d) using a ligation/extension mixture to extend and ligate the gap region between the two clip binding arms to form a single-stranded circular nucleic acid molecule; and

e) analyzing a plurality of amplicons that are amplified from single-stranded circular nucleic acid molecules of step d) to characterize the one or more nucleic acids of interest.

86. The method of claim 85, wherein analyzing a plurality of amplicons of step e) comprises determining one or more of size, size distribution, nucleotide sequence, and/or amounts one or more of said plurality of amplicons.

87. The method of claim 85 or 86, wherein amplifying the plurality of amplicons from single-stranded circular nucleic acid molecules comprises a polymerase chain reaction.

88. The method of any one of claims 85-87, wherein the plurality of target nucleic acids are double-stranded, and wherein one or both clip sequences are added by ligation.

89. The method of claim 88, wherein the double-stranded plurality of nucleic acids is subjected to one or more of end-repair, phosphorylation, and A-tailing prior to ligation of said one or both clip sequences.

90. The method of any one of claims 85-89, wherein the clip sequences added in step a) are added using target-specific adaptor oligonucleotides, wherein the target-specific adapter oligonucleotides comprise a sequence substantially complementary to a clip arm and a sequence substantially complementary to a 5′

or 3′

terminal portion of a target nucleic acid sequence of interest.

91. The method of any one of claims 85-90, further comprising prior to step c) a step of treating the clip product with bisulfate under conditions wherein unmethylated cytosines are converted to uracils.

92. The method of claim 91, wherein the clip sequences added in step b) do not comprise cytosines.

93. The method of any one of claims 85-92, wherein the method further comprises an exonuclease digestion step that digests non-circular, linear nucleic acids.

94. The method of claim 93, wherein, following the exonuclease digestion, the method further comprises a linearizing step wherein the single-stranded circular nucleic acid molecule is cleaved to become linear.

95. The method of any one of claims 86-94, wherein nucleotide sequences of at least 50,000 different nucleic acids from the subject are determined using a single capture probe.

96. The method of any one of claims 86-95, wherein the sizes of at least 1,000 different nucleic acids in the nucleic acid sample are determined using a single capture probe.